Insights+: Key Deals of JP Morgan Healthcare Conference 2021
Shots: Regenxbio has reported that the ATMOSPHERE trial evaluating RGX-314 is active and patient screening is ongoing. The study will enroll 300 patients across two RGX-314 dose arms vs ranibizumab, with anticipated initiation of patients dosing in Q1’21 The second trial is expected to be similar in design to ATMOSPHERE with its expected initiation in […]Read More